Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways

Hypothalamic obesity (HO) is a disabling disease caused by central nervous system (CNS) damage due to neurosurgery, trauma, or tumors, especially in hypothalamus. The pathological mechanism of its neural circuits is still unclear, and there is currently no corresponding drug due to the complex etiol...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Junjie Peng, Yichao Ou, Mingfeng Zhou, Xingqin Wang, Xi’an Zhang, Hao Long, Guangsen Wu, Mengjie Che, Kai Li, Le Yang, Zhu Zhang, Ken Kin Lam Yung, Songtao Qi, Zhanpeng Feng
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2026-01-01
Sarja:	Frontiers in Pharmacology
Aiheet:	CaMKK2/AMPK signaling GPCRs hypothalamic obesity melanocortin 4 receptor neuropharmacology setmelanotide
Linkit:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1730786/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!